The AC3’s Collaboration with Pfizer aims to address gaps in the treatment of cancer

Dr.George and Dr.Ragin from left to right

 

 

 

 In November 2022, Pfizer announced its collaboration with the George Lab at the Sylvester Comprehensive Cancer Center (SCCC) and the Ragin Lab at Fox Chase Cancer Center (FCCC). Both labs are part of the African Caribbean Cancer Consortium (AC3). This new study aims to classify novel genetic, molecular, and social determinants that impact cancer prognosis among those of African ancestry. “People of African ancestry disproportionately develop aggressive, high-grade cancers, particularly in breast and prostate tissues, and the underlying driving factors are not well understood,” says Dr.Sophia George Ph.D. Participation recruitment will occur in the United States, Africa, and the Caribbean. This study, with its wide network, will address the gaps in cancer treatment that will then lead to equitable health.

 View Articles below:

https://www.pfizer.com/news/press-release/press-release-detail/fox-chase-cancer-center-and-sylvester-comprehensive-cancer

 https://physician-news.umiamihealth.org/sylvester-and-fox-chase-cancer-center-collaborate-with-pfizers-institute-of-translational-equitable-medicine-to-identify-novel-genetic-drivers-of-cancer-disparities-in-african-ancestry-popula/